Scinai ends PC111 arrangements and refocuses on NanoAb, CDMO growth
AI Summary- Scinai ended its PC111 option and license arrangements with PinCell and redirected research resources.
- €12 million is sought through Poland's FENG program for an intradermal IL-17 psoriasis program.
- Scinai reported approximately $3.1 million in Committed Customer Orders as of August 16, 2026.